EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Prevalence of extended spectrum beta-lactamase -producing clinical isolates in the Asia-Pacific region and South Africa Regional results from SENTRY Antimicrobial Surveillance Program



Prevalence of extended spectrum beta-lactamase -producing clinical isolates in the Asia-Pacific region and South Africa Regional results from SENTRY Antimicrobial Surveillance Program



Diagnostic Microbiology & Infectious Disease 42(3): 193-198, March



The frequency of occurrence of ESBL-producing clinical strains varies widely in distinct geographic areas. The objective of this study was to describe the frequency of occurrence, the preferred substrate, and the co-resistance patterns of the ESBL-producing isolates collected from the Asia-Pacific region and South Africa through the SENTRY Antimicrobial Surveillance Program between January 1998 and December 1999. A total of 1,377 Escherichia coli, 678 Klebsiella pneumoniae, and 138 Proteus mirabilis isolates were collected from diverse body sites. Using NCCLS criteria, 139 E. coli (10.1%), 171 K. pneumoniae (25.2%), and 2 P. mirabilis (1.4%) had presumptive ESBL phenotypes; 100, 146 and 1 strain respectively were confirmed to be ESBL producers on clavulanate enhancement testing. The frequency of occurrence of confirmed ESBL-producing E. coli by the medical centers varied from 0-1% for centers located in Australia to 13-35% for mainland Chinese centers. The higher prevalence rates (>20%) of ESBL K. pneumoniae phenotypes were observed in all mainland Chinese centers, one Japanese and one Taiwanese center, and in the Philippine, South African, Singaporean and medical centers. The spread of the presumptive ESBL phenotype to the Enterobacter species was observed in nine medical centers. Overall, ceftriaxone and aztreonam were the best substrates for the detection of the ESBL phenotype between both E. coli isolates and K. pneumoniae ESBL phenotypes; however, there was significant variation between countries in substrate preference. Co-resistances to gentamicin, tobramycin, tetracycline, and trimethoprim-sulfamethoxazole were common throughout isolates collected from most medical centers. Ciprofloxacin resistance rates were very high among isolates collected from Hong Kong, mainland China, Singapore, and the Philippines. The best coverage against ESBL-producing isolates was obtained with imipenem (0% resistance), followed by amikacin (6% resistance).

(PDF emailed within 1 workday: $29.90)

Accession: 035548866

Download citation: RISBibTeXText



Related references

Prevalence of extended spectrum beta-lactamase (ESBL)-producing clinical isolates in the Asia-Pacific region and South Africa: regional results from SENTRY Antimicrobial Surveillance Program (1998-99). Diagnostic Microbiology and Infectious Disease 42(3): 193-198, 2002

Prevalence of extended-spectrum beta-lactamase-producing Enterobacter cloacae in the Asia-Pacific region: results from the SENTRY Antimicrobial Surveillance Program, 1998 to 2001. Antimicrobial Agents and ChemoTherapy 47(12): 3989-3993, 2003

Regional variation in the prevalence of extended-spectrum beta-lactamase-producing clinical isolates in the Asia-Pacific region (SENTRY 1998-2002). Diagnostic Microbiology and Infectious Disease 52(4): 323-329, 2005

Extended spectrum beta-lactamase phenotypes in enteric bacilli from the Asia-Pacific Region Report from the SENTRY antimicrobial surveillance Program. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 41: 117, 2001

High prevalence of oxacillin-resistant Staphylococcus aureus isolates from hospitalized patients in Asia-Pacific and South Africa: results from SENTRY antimicrobial surveillance program, 1998-1999. Antimicrobial Agents and ChemoTherapy 46(3): 879-881, 2002

Prevalence and significance of a negative extended-spectrum beta-lactamase (ESBL) confirmation test result after a positive ESBL screening test result for isolates of Escherichia coli and Klebsiella pneumoniae: results from the SENTRY Asia-Pacific Surveillance Program. Journal of Clinical Microbiology 45(5): 1478-1482, 2007

Rapidly emerging extended-spectrum beta-lactamase -producing Proteus mirabilis Results of SENTRY Antimicrobial Surveillance Program 1997-1998. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 39: 169, 1999

Prevalence and Significance of a Negative Extended-Spectrum o-Lactamase (ESBL) Confirmation Test Result after a Positive ESBL Screening Test Result for Isolates of Escherichia coli and Klebsiella pneumoniae: Results from the SENTRY Asia-Pacific Surveillance Program. Journal of clinical microbiology JCM 45(5): 1478-1482, 2007

SENTRY Antimicrobial Surveillance Program Asia-Pacific region and South Africa. Communicable Diseases Intelligence Quarterly Report 27 Suppl: S61-S66, 2003

Evolution and dissemination of extended-spectrum beta-lactamase-producing K pneumoniae Epidemiology and molecular report from the SENTRY Antimicrobial Surveillance Program during 1997-2003. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 43: 108, 2003

Evolution and dissemination of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae: epidemiology and molecular report from the SENTRY Antimicrobial Surveillance Program (1997-2003). Diagnostic Microbiology and Infectious Disease 51(1): 1-7, 2005

Clonal dissemination and expansion of extended spectrum beta-lactamase -producing K pneumoniae in a large metropolitan teaching hospital An epidemiologic history from the SENTRY antimicrobial surveillance program. Abstracts of the General Meeting of the American Society for Microbiology 103: C-393, 2003

Characterization of strains from Europe , North and Latin America and Western Pacific that express an extended spectrum beta-lactamase phenotype Report from the SENTRY antimicrobial surveillance program. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 40: 119, 2000

Diversity of extended-spectrum beta-lactamases in noninducible Enterobacteriaceae from the SENTRY surveillance program for Asia, Australia, and South Africa, 1998. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 39: 166, 1999

Emergence of extended-spectrum beta-lactamases in Enterobacter cloacae from the SENTRY surveillance program for the Western Pacific and South Africa , 1998-9. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 40: 119, 2000